Amplifying Curcumin’s Antitumor Potential: A Heat-Driven Approach for Colorectal Cancer Treatment

References

• Franko J, Shi Q, Meyers JP, et al. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. Lancet Oncol. 2016;17(12):1709–1719. doi:10.1016/S1470-2045(16)30500-9
   PubMed Web of Science ®Google Scholar
• Dawson LE, Russell AH, Tong D, Wisbeck WM. Adenocarcinoma of the sigmoid colon: sites of initial dissemination and clinical patterns of recurrence following surgery alone. J Surgical Oncol. 1983;22(2):95–99. doi:10.1002/jso.2930220208
   PubMed Web of Science ®Google Scholar
• Klaver YL, Lemmens VE, Creemers GJ, Rutten HJ, Nienhuijs SW, de Hingh IH. Population-based survival of patients with peritoneal carcinomatosis from colorectal origin in the era of increasing use of palliative chemotherapy. Ann Oncol. 2011;22(10):2250–2256. doi:10.1093/annonc/mdq762
   PubMed Web of Science ®Google Scholar
• Verwaal VJ, van Ruth S, de Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003;21(20):3737–3743. doi:10.1200/JCO.2003.04.187
   PubMed Web of Science ®Google Scholar
• Sugarbaker PH, Alderman R, Edwards G, et al. Prospective morbidity and mortality assessment of cytoreductive surgery plus perioperative intraperitoneal chemotherapy to treat peritoneal dissemination of appendiceal mucinous malignancy. Ann Surg Oncol. 2006;13(5):635–644. doi:10.1245/ASO.2006.03.079
   PubMed Web of Science ®Google Scholar
• da Silva RG, Sugarbaker PH. Analysis of prognostic factors in seventy patients having a complete cytoreduction plus perioperative intraperitoneal chemotherapy for carcinomatosis from colorectal cancer. J Am Coll Surg. 2006;203(6):878–886. doi:10.1016/j.jamcollsurg.2006.08.024
   PubMed Web of Science ®Google Scholar
• Marz L, Piso P. Treatment of peritoneal metastases from colorectal cancer. Gastroenterol Rep. 2015;3(4):298–302. doi:10.1093/gastro/gov044
   Google Scholar
• Bachmann C, Sautkin I, Nadiradze G, et al. Technology development of hyperthermic pressurized intraperitoneal aerosol chemotherapy (hPIPAC). Surg Endosc. 2021;35(11):6358–6365. doi:10.1007/s00464-021-08567-y
   PubMed Web of Science ®Google Scholar
• Weinreich J, Struller F, Sautkin I, et al. Chemosensitivity of various peritoneal cancer cell lines to HIPEC and PIPAC: comparison of an experimental duplex drug to standard drug regimens in vitro. Invest New Drugs. 2019;37(3):415–423. doi:10.1007/s10637-018-0641-6
   PubMed Web of Science ®Google Scholar
• Daniel SK, Sun BJ, Lee B. PIPAC for gastrointestinal malignancies. J Clin Med. 2023;12(21):1.
   Web of Science ®Google Scholar
• Schell F, Kefleyesus A, Benzerdjeb N, et al. Influence of extraperitoneal metastases on the curative-intent management of colorectal peritoneal metastases. Ann Surg Oncol. 2023;30(7):4444–4454. doi:10.1245/s10434-023-13279-9
   PubMedGoogle Scholar
• Ornella MSC, Badrinath N, Kim KA, et al. Immunotherapy for peritoneal carcinomatosis: challenges and prospective outcomes. Cancers. 2023;15(8):2383. doi:10.3390/cancers15082383
   PubMed Web of Science ®Google Scholar
• Taliento C, Restaino S, Scutiero G, et al. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with cisplatin and doxorubicin in patients with ovarian cancer: a systematic review. Eur J Surg Oncol. 2023;49(12):107250. doi:10.1016/j.ejso.2023.107250
   PubMed Web of Science ®Google Scholar
• Fallows M, Samant A, Wilson H, Mirnezami R. A systematic review of surgical management strategies in the treatment of peritoneal carcinomatosis of neuroendocrine origin. Curr Oncol. 2023;30(7):6316–6329. doi:10.3390/curroncol30070466
   PubMed Web of Science ®Google Scholar
• Klaver CE, Musters GD, Bemelman WA, et al. Adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with colon cancer at high risk of peritoneal carcinomatosis; the COLOPEC randomized multicentre trial. BMC Cancer. 2015;15:428. doi:10.1186/s12885-015-1430-7
   PubMed Web of Science ®Google Scholar
• Sommariva A, Tonello M, Coccolini F, et al. Colorectal cancer with peritoneal metastases: the impact of the results of PROPHYLOCHIP, COLOPEC, and PRODIGE 7 trials on peritoneal disease management. Cancers. 2022;15(1):165. doi:10.3390/cancers15010165
   PubMed Web of Science ®Google Scholar
• Huang CQ, Min Y, Wang SY, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival for peritoneal carcinomatosis from colorectal cancer: a systematic review and meta-analysis of current evidence. Oncotarget. 2017;8(33):55657–55683. doi:10.18632/oncotarget.17497
   PubMedGoogle Scholar
• Turaga K, Levine E, Barone R, et al. Consensus guidelines from The American Society of Peritoneal Surface Malignancies on standardizing the delivery of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer patients in the United States. Ann Surg Oncol. 2014;21(5):1501–1505. doi:10.1245/s10434-013-3061-z
   PubMed Web of Science ®Google Scholar
• Nadler A, McCart JA, Govindarajan A. Peritoneal carcinomatosis from colon cancer: a systematic review of the data for cytoreduction and intraperitoneal chemotherapy. Clin Colon Rectal Surg. 2015;28(4):234–246. doi:10.1055/s-0035-1564431
   PubMed Web of Science ®Google Scholar
• Murono K, Kawai K, Hata K, et al. Regimens of intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal cancer. Anticancer Res. 2018;38(1):15–22. doi:10.21873/anticanres.12186
   PubMed Web of Science ®Google Scholar
• Diaz Osterman CJ, Gonda A, Stiff T, et al. Curcumin induces pancreatic adenocarcinoma cell death via reduction of the inhibitors of apoptosis. Pancreas. 2016;45(1):101–109. doi:10.1097/MPA.0000000000000411
   PubMed Web of Science ®Google Scholar
• Shehzad A, Lee J, Lee YS. Curcumin in various cancers. Biofactors. 2013;39(1):56–68. doi:10.1002/biof.1068
   PubMed Web of Science ®Google Scholar
• Chainani-Wu N. Safety and anti-inflammatory activity of curcumin: a component of tumeric (Curcuma longa). J Altern Complement Med. 2003;9(1):161–168. doi:10.1089/107555303321223035
   PubMed Web of Science ®Google Scholar
• Zhang P, Lai ZL, Chen HF, et al. Curcumin synergizes with 5-fluorouracil by impairing AMPK/ULK1-dependent autophagy, AKT activity and enhancing apoptosis in colon cancer cells with tumor growth inhibition in xenograft mice. J Exp Clin Cancer Res. 2017;36(1):190. doi:10.1186/s13046-017-0661-7
   PubMedGoogle Scholar
• Shakibaei M, Buhrmann C, Kraehe P, Shayan P, Lueders C, Goel A. Curcumin chemosensitizes 5-fluorouracil resistant MMR-deficient human colon cancer cells in high density cultures. PLoS One. 2014;9(1):e85397. doi:10.1371/journal.pone.0085397
   PubMed Web of Science ®Google Scholar
• Garcea G, Jones DJ, Singh R, et al. Detection of curcumin and its metabolites in hepatic tissue and portal blood of patients following oral administration. Br J Cancer. 2004;90(5):1011–1015. doi:10.1038/sj.bjc.6601623
   PubMed Web of Science ®Google Scholar
• Sharma RA, Euden SA, Platton SL, et al. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res. 2004;10(20):6847–6854. doi:10.1158/1078-0432.CCR-04-0744
   PubMed Web of Science ®Google Scholar
• Garcea G, Berry DP, Jones DJ, et al. Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences. Cancer Epidemiol Biomarkers Prev. 2005;14(1):120–125. doi:10.1158/1055-9965.120.14.1
   PubMed Web of Science ®Google Scholar
• Carroll RE, Benya RV, Turgeon DK, et al. Phase IIa clinical trial of curcumin for the prevention of colorectal neoplasia. Cancer Prev Res. 2011;4(3):354–364. doi:10.1158/1940-6207.CAPR-10-0098
   PubMed Web of Science ®Google Scholar
• Zhang W, Cui T, Liu L, et al. Improving anti-tumor activity of curcumin by polymeric micelles in thermosensitive hydrogel system in colorectal peritoneal carcinomatosis model. J Biomed Nanotechnol. 2015;11(7):1173–1182. doi:10.1166/jbn.2015.2073
   PubMed Web of Science ®Google Scholar
• Xu XY, Meng X, Li S, Gan RY, Li Y, Li HB. Bioactivity, health benefits, and related molecular mechanisms of curcumin: current progress, challenges, and perspectives. Nutrients. 2018;10(10):1553. doi:10.3390/nu10101553
   PubMed Web of Science ®Google Scholar
• Khan S, Jutzy JM, Aspe JR, McGregor DW, Neidigh JW, Wall NR. Survivin is released from cancer cells via exosomes. Apoptosis. 2011;16(1):1–12. doi:10.1007/s10495-010-0534-4
   PubMed Web of Science ®Google Scholar
• de Cuba EM, Kwakman R, Knol DL, et al. Cytoreductive surgery and HIPEC for peritoneal metastases combined with curative treatment of colorectal liver metastases: systematic review of all literature and meta-analysis of observational studies. Cancer Treat Rev. 2013;39(4):321–327. doi:10.1016/j.ctrv.2012.11.003
   PubMed Web of Science ®Google Scholar
• Goodman MD, McPartland S, Detelich D, Saif MW. Chemotherapy for intraperitoneal use: a review of hyperthermic intraperitoneal chemotherapy and early post-operative intraperitoneal chemotherapy. J Gastrointest Oncol. 2016;7(1):45–57. doi:10.3978/j.issn.2078-6891.2015.111
   PubMedGoogle Scholar
• Lemoine L, Sugarbaker P, Van der Speeten K. Drugs, doses, and durations of intraperitoneal chemotherapy: standardising HIPEC and EPIC for colorectal, appendiceal, gastric, ovarian peritoneal surface malignancies and peritoneal mesothelioma. Int J Hyperthermia. 2017;33(5):582–592. doi:10.1080/02656736.2017.1291999
   PubMed Web of Science ®Google Scholar
• Zhu C, Fang Z, Peng L, Gao F, Peng W, Song F. Curcumin suppresses the progression of colorectal cancer by improving immunogenic cell death caused by irinotecan. Chemotherapy. 2022;67(4):211–222. doi:10.1159/000518121
   PubMed Web of Science ®Google Scholar
• Ojo OA, Adeyemo TR, Rotimi D, et al. Anticancer properties of curcumin against colorectal cancer: a review. Front Oncol. 2022;12:881641. doi:10.3389/fonc.2022.881641
   PubMed Web of Science ®Google Scholar
• Li M, Guo T, Lin J, et al. Curcumin inhibits the invasion and metastasis of triple negative breast cancer via Hedgehog/Gli1 signaling pathway. J Ethnopharmacol. 2022;283:114689. doi:10.1016/j.jep.2021.114689
   PubMed Web of Science ®Google Scholar
• Firouzi Amandi A, Jokar E, Eslami M, et al. Enhanced anti-cancer effect of artemisinin- and curcumin-loaded niosomal nanoparticles against human colon cancer cells. Med Oncol. 2023;40(6):170. doi:10.1007/s12032-023-02032-7
   PubMed Web of Science ®Google Scholar
• He Q, Liu C, Wang X, et al. Exploring the mechanism of curcumin in the treatment of colon cancer based on network pharmacology and molecular docking. Front Pharmacol. 2023;14:1102581. doi:10.3389/fphar.2023.1102581
   PubMedGoogle Scholar
• Shojaei M, Sahebkar A, Khorvash F, Fallahpour S, Askari G, Bagherniya M. The effects of phytosomal curcumin supplementation on clinical symptoms, and inflammatory and oxidative stress biomarkers in patients with migraine: a protocol for a randomized double-blind placebo-controlled trial. Avicenna J Phytomed. 2023;13(1):45–57. doi:10.22038/AJP.2022.21242
   PubMedGoogle Scholar
• Hu Z, Tang Y, Jiang B, Xu Y, Liu S, Huang C. Functional liposome loaded curcumin for the treatment of Streptococcus mutans biofilm. Front Chem. 2023;11:1160521. doi:10.3389/fchem.2023.1160521
   PubMed Web of Science ®Google Scholar
• Garcia-Cuellar CM, Hernandez-Delgadillo R, Torres-Betancourt JA, et al. Cumulative antitumor effect of bismuth lipophilic nanoparticles and cetylpyridinium chloride in inhibiting the growth of lung cancer. J Appl Biomater Funct Mater. 2023;21:22808000231161177. doi:10.1177/22808000231161177
   Web of Science ®Google Scholar
• Li M, Tao J, Qian R, et al. Development of alternative herbals remedy for gastric cancer based on transcriptomic analysis of immune infiltration and ferroptosis. Front Genet. 2023;14:1086368. doi:10.3389/fgene.2023.1086368
   PubMed Web of Science ®Google Scholar
• Idoudi S, Bedhiafi T, Hijji YM, Billa N. Curcumin and derivatives in nanoformulations with therapeutic potential on colorectal cancer. AAPS Pharm Sci Tech. 2022;23(5):115. doi:10.1208/s12249-022-02268-y
   PubMed Web of Science ®Google Scholar
• Weng W, Goel A. Curcumin and colorectal cancer: an update and current perspective on this natural medicine. Semin Cancer Biol. 2022;80:73–86. doi:10.1016/j.semcancer.2020.02.011
   PubMed Web of Science ®Google Scholar
• Wang Y, Lu J, Jiang B, Guo J. The roles of curcumin in regulating the tumor immunosuppressive microenvironment. Oncol Lett. 2020;19(4):3059–3070. doi:10.3892/ol.2020.11437
   PubMed Web of Science ®Google Scholar
• Irving GR, Iwuji CO, Morgan B, et al. Combining curcumin (C3-complex, Sabinsa) with standard care FOLFOX chemotherapy in patients with inoperable colorectal cancer (CUFOX): study protocol for a randomised control trial. Trials. 2015;16(1):110. doi:10.1186/s13063-015-0641-1
   PubMedGoogle Scholar
• Sinha D, Biswas J, Sung B, Aggarwal BB, Bishayee A. Chemopreventive and chemotherapeutic potential of curcumin in breast cancer. Curr Drug Targets. 2012;13(14):1799–1819. doi:10.2174/138945012804545632
   PubMed Web of Science ®Google Scholar
• Sadeghi M, Dehnavi S, Asadirad A, et al. Curcumin and chemokines: mechanism of action and therapeutic potential in inflammatory diseases. Inflammopharmacology. 2023;31(3):1069–1093. doi:10.1007/s10787-023-01136-w
   PubMed Web of Science ®Google Scholar
• Zhang H, Li H, Wang H, Lei S, Yan L. Overexpression of TRPM7 promotes the therapeutic effect of curcumin in wound healing through the STAT3/SMAD3 signaling pathway in human fibroblasts. Burns. 2023;49(4):889–900. doi:10.1016/j.burns.2022.06.016
   PubMed Web of Science ®Google Scholar
• Lev-Ari S, Strier L, Kazanov D, et al. Curcumin synergistically potentiates the growth-inhibitory and pro-apoptotic effects of celecoxib in osteoarthritis synovial adherent cells. Rheumatology. 2006;45(2):171–177. doi:10.1093/rheumatology/kei132
   PubMed Web of Science ®Google Scholar
• Naylor G, Julian L, Watson-Bryce S, Mullin M, Nibbs RJ, Olson MF. Immunogenic death of hepatocellular carcinoma cells in mice expressing caspase-resistant ROCK1 is not replicated by ROCK inhibitors. Cancers. 2022;14(23). doi:10.3390/cancers14235943
   PubMed Web of Science ®Google Scholar
• Bao X, Xie L. Targeting purinergic pathway to enhance radiotherapy-induced immunogenic cancer cell death. J Exp Clin Cancer Res. 2022;41(1):222. doi:10.1186/s13046-022-02430-1
   PubMed Web of Science ®Google Scholar
• Zhou Y, Liu C, Song H. Innate immunomodulatory nanodevices for cancer therapy: a review. J Biomed Nanotechnol. 2022;18(2):293–318. doi:10.1166/jbn.2022.3241
   PubMed Web of Science ®Google Scholar
• Mao L, Zhou JJ, Xiao Y, et al. Immunogenic hypofractionated radiotherapy sensitising head and neck squamous cell carcinoma to anti-PD-L1 therapy in MDSC-dependent manner. Br J Cancer. 2023;128(11):2126–2139. doi:10.1038/s41416-023-02230-0
   PubMed Web of Science ®Google Scholar
• Calvillo-Rodriguez KM, Lorenzo-Anota HY, Rodriguez-Padilla C, Martinez-Torres AC, Scott-Algara D. Immunotherapies inducing immunogenic cell death in cancer: insight of the innate immune system. Front Immunol. 2023;14:1294434. doi:10.3389/fimmu.2023.1294434
   PubMed Web of Science ®Google Scholar
• Aarts F, Hendriks T, Boerman OC, Koppe MJ, Oyen WJ, Bleichrodt RP. A comparison between radioimmunotherapy and hyperthermic intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis of colonic origin in rats. Ann Surg Oncol. 2007;14(11):3274–3282. doi:10.1245/s10434-007-9509-2
   PubMed Web of Science ®Google Scholar
• Gajardo JA, Matute J, Charles R, et al. Starting a peritoneal carcinomatosis treatment program in a developing country: a prospective analysis. J Surg Oncol. 2021;124(7):1154–1160. doi:10.1002/jso.26626
   PubMed Web of Science ®Google Scholar
• Lehmann K, Rickenbacher A, Jang JH, et al. New insight into hyperthermic intraperitoneal chemotherapy: induction of oxidative stress dramatically enhanced tumor killing in in vitro and in vivo models. Ann Surg. 2012;256(5):730–738. doi:10.1097/SLA.0b013e3182737517
   PubMed Web of Science ®Google Scholar
• Woeste MR, Philips P, Egger ME, Scoggins CR, McMasters KM, Martin RCG. Optimal perfusion chemotherapy: a prospective comparison of mitomycin C and oxaliplatin for hyperthermic intraperitoneal chemotherapy in metastatic colon cancer. J Surg Oncol. 2020;121(8):1298–1305. doi:10.1002/jso.25920
   PubMed Web of Science ®Google Scholar
• Choudhary HB, Mandlik SK, Mandlik DS. Role of p53 suppression in the pathogenesis of hepatocellular carcinoma. World J Gastrointest Pathophysiol. 2023;14(3):46–70. doi:10.4291/wjgp.v14.i3.46
   PubMedGoogle Scholar
• Ghantous L, Volman Y, Hefez R, et al. The DNA damage response pathway regulates the expression of the immune checkpoint CD47. Commun Biol. 2023;6(1):245. doi:10.1038/s42003-023-04615-6
   PubMed Web of Science ®Google Scholar
• Gao SB, Li KL, Qiu H, et al. Enhancing chemotherapy sensitivity by targeting PcG via the ATM/p53 pathway. Am J Cancer Res. 2017;7(9):1874–1883.
   PubMed Web of Science ®Google Scholar
• Ottaggio L, Campomenosi P, Fronza G, et al. Stable formation of mutated p53 multimers in a Chinese hamster cell line causes defective p53 nuclear localization and abrogates its residual function. J Cell Biochem. 2006;98(6):1689–1700. doi:10.1002/jcb.20921
   PubMed Web of Science ®Google Scholar
• Zhang J, Li L, Yin J, Zhang X, Zheng Y, Feng R. Study on the thermal stability of nab-paclitaxel during hyperthermic intraperitoneal chemotherapy. BMC Pharmacol Toxicol. 2023;24(1):13. doi:10.1186/s40360-023-00653-2
   PubMed Web of Science ®Google Scholar
• Murata S, Yamamoto H, Naitoh H, et al. Feasibility and safety of hyperthermic intraperitoneal chemotherapy using 5-fluorouracil combined with cisplatin and mitomycin C in patients undergoing gastrectomy for advanced gastric cancer. J Surg Oncol. 2017;116(8):1159–1165. doi:10.1002/jso.24771
   PubMed Web of Science ®Google Scholar
• Spiliotis J, Rogdakis A, Vaxevanidou A, Datsis A, Zacharis G, Christopoulou A. Morbidity and mortality of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal carcinomatosis. J BUON. 2009;14(2):259–264.
   PubMed Web of Science ®Google Scholar
• Fan B, Bu Z, Zhang J, et al. Phase II trial of prophylactic hyperthermic intraperiton eal chemotherapy in patients with locally advanced gastric cancer after curative surgery. BMC Cancer. 2021;21(1):216. doi:10.1186/s12885-021-07925-2
   PubMed Web of Science ®Google Scholar
• Kusamura S, Baratti D, Younan R, et al. Impact of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy on systemic toxicity. Ann Surg Oncol. 2007;14(9):2550–2558. doi:10.1245/s10434-007-9429-1
   PubMed Web of Science ®Google Scholar
• Ceelen WP, Peeters M, Houtmeyers P, Breusegem C, De Somer F, Pattyn P. Safety and efficacy of hyperthermic intraperitoneal chemoperfusion with high-dose oxaliplatin in patients with peritoneal carcinomatosis. Ann Surg Oncol. 2008;15(2):535–541. doi:10.1245/s10434-007-9648-5
   PubMed Web of Science ®Google Scholar
• Sugarbaker PH, Stuart OA, Carmignani CP. Pharmacokinetic changes induced by the volume of chemotherapy solution in patients treated with hyperthermic intraperitoneal mitomycin C. Cancer Chemother Pharmacol. 2006;57(5):703–708. doi:10.1007/s00280-005-0074-8
   PubMed Web of Science ®Google Scholar
• Jacquet P, Averbach A, Stephens AD, Stuart OA, Chang D, Sugarbaker PH. Heated intraoperative intraperitoneal mitomycin C and early postoperative intraperitoneal 5-fluorouracil: pharmacokinetic studies. Oncology. 1998;55(2):130–138. doi:10.1159/000011847
   PubMed Web of Science ®Google Scholar
• Fujimoto S, Takahashi M, Kobayashi K, et al. Metabolic changes in cimetidine treatment for scald injury on the peritoneo-serosal surface in far-advanced gastric cancer patients treated by intraperitoneal hyperthermic perfusion. Surg Today. 1993;23(5):396–401. doi:10.1007/BF00309496
   PubMed Web of Science ®Google Scholar
• Fan Z, Jing H, Yao J, et al. The protective effects of curcumin on experimental acute liver lesion induced by intestinal ischemia-reperfusion through inhibiting the pathway of NF-kappaB in a rat model. Oxid Med Cell Longev. 2014;2014:191624. doi:10.1155/2014/191624
   PubMed Web of Science ®Google Scholar
• Chen MJ, Cheng YM, Lai PH, Wu JF, Hsu YC. In vitro biocompatibility of thermally gelling liquid mucoadhesive loaded curcuminoids in colorectal cancer chemoprevention. Int J Colorectal Dis. 2012;27(7):869–878. doi:10.1007/s00384-011-1393-3
   PubMed Web of Science ®Google Scholar
• Spiliotis J, Tentes AA, Vaxevanidou A, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal carcinomatosis. Preliminary results and cost from two centers in Greece. J BUON. 2008;13(2):205–210.
   PubMed Web of Science ®Google Scholar
• Canda AE, Arslan C, Terzi C, et al. Treatment of intraoperatively detected peritoneal carcinomatosis of colorectal origin with cytoreductive surgery and intraperitoneal chemotherapy. World J Surg Oncol. 2018;16(1):70.
   PubMedGoogle Scholar
• Aarts F, Bleichrodt RP, de Man B, Lomme R, Boerman OC, Hendriks T. The effects of adjuvant experimental radioimmunotherapy and hyperthermic intraperitoneal chemotherapy on intestinal and abdominal healing after cytoreductive surgery for peritoneal carcinomatosis in the rat. Ann Surg Oncol. 2008;15(11):3299–3307. doi:10.1245/s10434-008-0070-4
   PubMed Web of Science ®Google Scholar
• Luo C, Cen S, Ding G, Wu W. Mucinous colorectal adenocarcinoma: clinical pathology and treatment options. Cancer Commun. 2019;39(1):13. doi:10.1186/s40880-019-0361-0
   Web of Science ®Google Scholar
• Peng HH, Huang YT, Cheng ZX, Lee CL, Lin CT. Immunomodulating therapy by picibanil-based imiquimod and virotherapy for advanced uterine cancer after laparoscopic surgery. Gynecol Minim Invasive Ther. 2021;10(3):191–194. doi:10.4103/GMIT.GMIT_153_20
   PubMed Web of Science ®Google Scholar
• Bienkowska A, Kuzmicka W, Ciepiela O, Ochocki J, Malecki M. Increased temperature facilitates adeno-associated virus vector transduction of colorectal cancer cell lines in a manner dependent on heat shock protein signature. Biomed Res Int. 2020;2020:9107140. doi:10.1155/2020/9107140
   PubMed Web of Science ®Google Scholar